Physician profile
James E Babashak
NPI 1932102803
$483.98
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.56 · 2022: $68.55 · 2023: $96.14 · 2024: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $140.17 | 2023-2024 | Entyvio |
| Celgene Corporation | $111.53 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $98.69 | 2024 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.63 | 2019-2023 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $29.90 | 2022-2023 | Dupixent |
| Lemaitre Vascular, INC. | $24.11 | 2024 | Hydro Lemaitre Valvulotome |
| Redhill Biopharma INC. | $14.50 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Babashak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.